Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials

Journal of Thrombosis and Haemostasis - Tập 19 - Trang 3080-3089 - 2021
Azita H. Talasaz1,2,3, Parham Sadeghipour4, Maryam Aghakouchakzadeh1, Hessam Kakavand1, Hamid Ariannejad2, Jean M. Connors5, Beverley J. Hunt6, Jeffrey S. Berger7, Benjamin W. Van Tassell3,8, Saskia Middeldorp9, Gregory Piazza10, Jeffrey I. Weitz11,12, Mary Cushman13,14, Gregory Y.H. Lip15,16, Samuel Z. Goldhaber10, Behnood Bikdeli10,17,18
1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
3Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
4Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research, Center, Iran University of Medical Sciences, Tehran, Iran
5Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
6Haemostasis and Thrombosis Centre, St Thomas’ Hospital, London, UK
7Leon H. Charney Division of Cardiology, Department of Medicine, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, New York, USA
8Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
9Department of Internal Medicine & Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, the Netherlands
10Cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
11Department of Medicine, McMaster University, Hamilton, Ontario, Canada
12Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
13Department of Medicine, University of Vermont Larner College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA
14Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA
15Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, UK
16Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
17Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA
18Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, USA

Tài liệu tham khảo

Bikdeli, 2020, COVID‐19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow‐up: JACC state‐of‐the‐art review, J Am Coll Cardiol, 75, 2950, 10.1016/j.jacc.2020.04.031 Iba, 2021, Ethnic differences in thromboprophylaxis for COVID‐19 patients: should they be considered?, Int J Hematol, 113, 330, 10.1007/s12185-021-03078-x Li, 2021, Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID‐19 patients: a multicenter retrospective study, J Thromb Haemost, 19, 1038, 10.1111/jth.15261 Talasaz, 2021, Recent randomized trials of antithrombotic therapy for patients with COVID‐19: JACC state‐of‐the‐art review, J Am Coll Cardiol, 77, 1903, 10.1016/j.jacc.2021.02.035 2021, Therapeutic anticoagulation with heparin in critically Ill patients with Covid‐19, N Engl J Med, 385, 777, 10.1056/NEJMoa2103417 Sadeghipour, 2021, JAMA, 325, 1620, 10.1001/jama.2021.4152 Perepu, 2021, Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: a multi‐center, open‐label, randomised controlled trial. open‐label, randomised controlled trial, J Thromb Haemost, 19, 2225, 10.1111/jth.15450 Bikdeli, 2021, Intermediate‐dose versus standard‐dose prophylactic anticoagulation in patients with COVID‐19 admitted to the intensive care unit: 90‐day results from the INSPIRATION randomized trial, Thromb Haemost Lopes, 2021, Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID‐19 and elevated D‐dimer concentration (ACTION): an open‐label, multicentre, randomised, controlled trial, Lancet, 397, 2253, 10.1016/S0140-6736(21)01203-4 Fauvel, 2020, Pulmonary embolism in COVID‐19 patients: a French multicentre cohort study, Eur Heart J, 41, 3058, 10.1093/eurheartj/ehaa500 De Pont, 2004, Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin‐10 response in human endotoxemia, J Thromb Haemost, 2, 65, 10.1111/j.1538-7836.2004.00526.x Zwart, 2020, New antithrombotic drugs in acute coronary syndrome, Clin Med, 9, 2059 Alschuler, 2020, Integrative considerations during the COVID‐19 pandemic, Explore (NY), 16, 354, 10.1016/j.explore.2020.03.007 Hoffmann, 2020, SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Saul, 2020, Old drugs for a new virus: repurposed approaches for combating COVID‐19, ACS Infect Dis, 6, 2304, 10.1021/acsinfecdis.0c00343 Li, 2018, Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‐β1, TNF‐α and NF‐κB. Mol Med Rep, 17, 1717 McCracken, 2020, Lack of evidence of ACE2 expression and replicative infection by SARSCoV‐2 in human endothelial cells, Circulation, 143, 865, 10.1161/CIRCULATIONAHA.120.052824 Libby, 2020, COVID‐19 is, in the end, an endothelial disease, Eur Heart J, 41, 3038, 10.1093/eurheartj/ehaa623 Neri, 2020, P‐selectin blockade in COVID‐19‐related ARDS, Am J Physiol Lung Cell Mol Physiol, 318, L1237, 10.1152/ajplung.00202.2020 Horiuchi, 2016, Complement‐targeted therapy: development of C5‐and C5a‐targeted inhibition, Inflamm Regen, 36, 1, 10.1186/s41232-016-0013-6 Gavriilaki, 2020, Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily, Br J Haematol, 189, e227, 10.1111/bjh.16783 Conway, 2020, Is the COVID‐19 thrombotic catastrophe complement‐connected?, J Thromb Haemost, 18, 2812, 10.1111/jth.15050 Annane, 2020, Eculizumab as an emergency treatment for adult patients with severe COVID‐19 in the intensive care unit: a proof‐of‐concept study, Eclin Med, 28, 100590 Echart, 2009, The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity, Blood Coagul Fibrinolysis, 20, 627, 10.1097/MBC.0b013e32832da1e3 Macciò, 2020, Multifactorial pathogenesis of COVID‐19‐related coagulopathy: can defibrotide have a role in the early phases of coagulation disorders?, J Thromb Haemost, 18, 3106, 10.1111/jth.15021 Calabretta, 2021, COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies, Br J Haematol, 193, 43, 10.1111/bjh.17240 Macciò, 2020, Defibrotide in the COVID‐19 coagulopathy: What is the timing?, J Thromb Haemost, 18, 3113, 10.1111/jth.15100
Thông tin
Thông tin xuất bản

Journal of Thrombosis and Haemostasis

Tập 19

3080-3089

Thông tin tác giả